News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
159 Results
Type
Article (22)
Press Release (137)
Section
Business (51)
Deals (2)
Drug Development (17)
FDA (2)
Job Trends (2)
News (67)
Policy (3)
Tag
Alliances (19)
Approvals (2)
Artificial intelligence (1)
Clinical research (12)
Collaboration (2)
COVID-19 (2)
Data (2)
Diabetes (2)
Diagnostics (1)
Drug discovery (1)
Earnings (9)
Events (22)
FDA (2)
Funding (1)
GLP-1 (1)
Government (1)
Healthcare (1)
Infectious disease (2)
IPO (4)
Job creations (1)
Layoffs (1)
Legal (1)
Medical device (2)
Medtech (2)
Mergers & acquisitions (2)
Metabolic disorders (9)
NextGen: Class of 2025 (1)
Obesity (8)
People (17)
Phase I (4)
Phase II (7)
Pipeline (4)
Preclinical (4)
Real estate (1)
Regulatory (2)
Startups (1)
Venture capital (1)
Weight loss (4)
Date
Last 7 days (1)
Last 30 days (3)
Last 365 days (29)
2025 (10)
2024 (28)
2023 (6)
2022 (25)
2021 (16)
2020 (9)
2019 (4)
2018 (2)
2017 (4)
2016 (4)
2015 (10)
2014 (4)
2013 (6)
2012 (5)
2011 (7)
2010 (3)
Location
Arizona (1)
Asia (11)
California (13)
Canada (1)
China (1)
Delaware (1)
Europe (15)
Idaho (1)
Massachusetts (1)
Northern California (9)
United States (17)
159 Results for "bioage".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
BioAge Drops Lead Obesity Asset Months After IPO
It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after the molecule caused liver-based side effects.
January 28, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
June 3, 2025
·
8 min read
Press Releases
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
·
9 min read
Press Releases
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 23, 2025
·
7 min read
Press Releases
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 29, 2025
·
8 min read
IPO
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its Phase III STRIDES study and into a registrational Phase III trial.
September 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
BioAge Labs to Participate in TD Cowen’s 45th Annual Health Care Conference
February 21, 2025
·
1 min read
Press Releases
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
January 29, 2025
·
5 min read
Press Releases
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
March 20, 2025
·
11 min read
Press Releases
BioAge Labs to Present at Upcoming Investor Conferences
November 22, 2024
·
1 min read
1 of 16
Next
